GILD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Gilead Sciences Inc (GILD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and robust growth in its HIV franchise outweigh short-term price declines. The stock is well-positioned for long-term growth, supported by solid fundamentals and a favorable outlook.
The technical indicators are generally bullish. The MACD is above zero and positively contracting, indicating upward momentum. The RSI is neutral at 62.482, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are at 148.071 (pivot), 155.192 (R1), and 140.951 (S1). Despite a recent price decline, the stock remains above key support levels, suggesting resilience.
Strong Q4 financial performance with revenue growth of 4.7% YoY and net income growth of 22.43% YoY.
Positive analyst sentiment with multiple price target upgrades, including a high target of $
Continued strength in the HIV franchise and potential upside in Yeztugo guidance.
Consistent dividend payments, providing income stability for long-term investors.
Weak financial guidance for 2026, which may cause short-term uncertainty.
Recent price decline of -2.56% in the regular market and -1.96% in pre-market trading.
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
In Q4 2025, Gilead reported revenue of $7.93 billion, up 4.7% YoY, and net income of $2.18 billion, up 22.43% YoY. EPS increased by 25.18% YoY to $1.74, and gross margin improved slightly to 79.57%. The company's strong financial performance highlights its growth potential, particularly in its HIV franchise.
Analysts are overwhelmingly positive on Gilead, with multiple firms raising price targets. Notable upgrades include Scotiabank ($177), Morgan Stanley ($171), and Needham ($170). Analysts cite strong Q4 results, durable HIV growth, and potential upside from Yeztugo guidance as key drivers for their optimism.
